Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-30
2010-10-05
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S416000
Reexamination Certificate
active
07807704
ABSTRACT:
The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
REFERENCES:
patent: 5612360 (1997-03-01), Boyd et al.
patent: 6864265 (2005-03-01), Bridger et al.
patent: 2003/0148940 (2003-08-01), Tudan et al.
patent: 2003/0232818 (2003-12-01), Anderson et al.
patent: 2005/0002939 (2005-01-01), Zlotnik et al.
patent: WO 9403483 (1994-02-01), None
patent: WO 99/56765 (1999-11-01), None
patent: WO 2005/000333 (2006-01-01), None
patent: WO 2007/115232 (2007-10-01), None
patent: WO 2007/115232 (2007-10-01), None
Nicolaou et al.; “The CP Molecule Labyrinth: A Paradigm of How Endeavors in Total Synthesis Lead to Discoveries and Inventions in Organic Synthesis”; 2002; Angew. Chem. Int. Ed.; 41: 2678-2720.
Yang. Tetrahedron Letters, 2000, 41, 6981-84.
Busillo, J.M. et al., “Regulation of CXCR4 Signaling,”Biochimica et Biophysica Acta, Nov. 10, 2006, vol. 1768, pp. 952-963.
Dairaghi, D.J. et al., “Chemokine Receptor CCR3 Function is Highly Dependent on Local pH and Ionic Strength,”The Journal of Biological Chemistry, Nov. 7, 1997, vol. 272, No. 45, pp. 28206-28209.
Dairaghi, D.J. et al., “HHV8-Encoded vMIP-I Selectively Engages Chemokine Receptor GCR8. Agonist and antagonist Profiles of Viral Chemokines,”The Journal of Biological Chemistry, Jul. 30, 1999, vol. 274, No. 31, pp. 21569-21574.
Gosling, J. et al., “Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK,”J. Immunol., Mar. 15, 2000, vol. 164, No. 6, pp. 2851-2856.
Paluchowska, M.H. et al., “Structure Activity Relationship Studies of CNS Agents. Effect of the Amide Fragment on 5-HT1AReceptor Activity of Some Analogs of MP 3022,”Polish Journal of Medicinal Chemistry, 1999, vol. 51, No. 5, pp. 415-421.
Penfold, M.E.T. et al., “Cytomegalovirus Encodes a Potent α Chemokine,”Proc. Natl. Acad. Sci. USA, Aug. 1999, vol. 96, pp. 9839-9844.
Leleti Manmohan Reddy
Pennell Andrew M. K.
Thomas William D.
Chemocentryx, Inc.
Jarrell Noble
Townsend and Townsend / and Crew LLP
Wilson James O
LandOfFree
Bicyclic, nitrogen-containing compounds modulating CXCR4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic, nitrogen-containing compounds modulating CXCR4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic, nitrogen-containing compounds modulating CXCR4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195896